These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 3342412

  • 41. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K.
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [Abstract] [Full Text] [Related]

  • 42. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.
    Donehower RC, Karp JE, Burke PJ.
    Cancer Treat Rep; 1986 Sep; 70(9):1059-65. PubMed ID: 3461882
    [Abstract] [Full Text] [Related]

  • 43. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ.
    Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
    [Abstract] [Full Text] [Related]

  • 44. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer.
    Schilsky RL, Muscato JJ, Muscato MS, Perry MC.
    Cancer Treat Rep; 1984 Sep; 68(9):1097-102. PubMed ID: 6541094
    [Abstract] [Full Text] [Related]

  • 45. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A, van Groeningen CJ, Kraal I, Gall H, Peters GJ, Lankelma J, Pinedo HM.
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [Abstract] [Full Text] [Related]

  • 46. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL.
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [Abstract] [Full Text] [Related]

  • 47. Is there a relationship between cytarabine pharmacokinetics and keratitis?--A case report.
    Boos J, Bömelburg T, Gerding H, Jürgens H.
    Int J Clin Pharmacol Ther Toxicol; 1993 Dec; 31(12):593-6. PubMed ID: 8314360
    [Abstract] [Full Text] [Related]

  • 48. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
    Lemez P, Urbánek V.
    Neoplasma; 2005 Dec; 52(5):398-401. PubMed ID: 16151584
    [Abstract] [Full Text] [Related]

  • 49. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Hug V, Keating MJ, Chubb S.
    Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
    [Abstract] [Full Text] [Related]

  • 50. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
    Yamauchi T, Kawai Y, Kishi S, Goto N, Urasaki Y, Imamura S, Fukushima T, Yoshida A, Iwasaki H, Tsutani H, Masada M, Ueda T.
    Jpn J Cancer Res; 2001 May; 92(5):546-53. PubMed ID: 11376564
    [Abstract] [Full Text] [Related]

  • 51. Clinical pharmacology of 1-beta-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion.
    Ho DH, Brown N, Lin JR, Covington W, Newman RA, Raber M, Amato R, Schmidt S, Krakoff IH.
    Drug Metab Dispos; 1991 May; 19(3):643-7. PubMed ID: 1717216
    [Abstract] [Full Text] [Related]

  • 52. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
    Mekras JA, Boothman DA, Greer SB.
    Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
    [Abstract] [Full Text] [Related]

  • 53. Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells.
    Ho DH, Carter CJ, Brown NS, Hester J, McCredie K, Benjamin RS, Freireich EJ, Bodey GP.
    Cancer Res; 1980 Jul; 40(7):2444-6. PubMed ID: 6248205
    [No Abstract] [Full Text] [Related]

  • 54. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 55. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
    Ellens H, Rustum Y, Mayhew E, Ledesma E.
    J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
    [Abstract] [Full Text] [Related]

  • 56. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 Aug; 82(6):664-7. PubMed ID: 9499665
    [Abstract] [Full Text] [Related]

  • 57. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K, Tsuruo T, Naganuma K, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [Abstract] [Full Text] [Related]

  • 58. Distribution of [3H]cytosine arabinoside and its products in mice, dogs, and monkeys and effect of tetrahydrouridine.
    Dareer SM, Mulligan LT, White V, Tillery K, Mellett LB, Hill DL.
    Cancer Treat Rep; 1977 Jan; 61(3):395-407. PubMed ID: 406044
    [No Abstract] [Full Text] [Related]

  • 59. Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.
    Ueda T, Nakamura T, Kagawa D, Uchida M, Domae N, Sugiyama M, Ueda Y, Sasada M, Uchino H.
    Cancer Chemother Pharmacol; 1989 Jan; 24(6):371-5. PubMed ID: 2791191
    [Abstract] [Full Text] [Related]

  • 60. Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
    Horber DH, Schott H, Schwendener RA.
    Br J Cancer; 1995 May; 71(5):957-62. PubMed ID: 7734320
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.